Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1964 1
1965 1
1967 2
1969 4
1970 1
1971 5
1975 1
1976 4
1979 2
1980 1
1981 2
1982 1
1983 2
1984 2
1985 1
1986 4
1987 4
1988 4
1989 3
1990 1
1991 4
1992 2
1993 3
1995 4
1996 6
1997 3
1998 10
1999 7
2000 12
2001 9
2002 17
2003 14
2004 14
2005 16
2006 15
2007 14
2008 9
2009 10
2010 12
2011 14
2012 22
2013 21
2014 26
2015 30
2016 28
2017 23
2018 29
2019 34
2020 25
2021 41
2022 28
Text availability
Article attribute
Article type
Publication date

Search Results

497 results
Results by year
Filters applied: . Clear all
Page 1
Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC.
Shirasawa M, Yoshida T, Shimoda Y, Takayanagi D, Shiraishi K, Kubo T, Mitani S, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Ichikawa H, Kohno T, Yamamoto N, Matsumoto S, Goto K, Watanabe SI, Ohe Y, Motoi N. Shirasawa M, et al. Among authors: okuma y. J Thorac Oncol. 2021 Dec;16(12):2078-2090. doi: 10.1016/j.jtho.2021.07.027. Epub 2021 Aug 20. J Thorac Oncol. 2021. PMID: 34419685
Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial.
Hamada H, Suzuki H, Onouchi Y, Ebata R, Terai M, Fuse S, Okajima Y, Kurotobi S, Hirai K, Soga T, Ishiguchi Y, Okuma Y, Takada N, Yanai M, Sato J, Nakayashiro M, Ayusawa M, Yamamoto E, Nomura Y, Hashimura Y, Ouchi K, Masuda H, Takatsuki S, Hirono K, Ariga T, Higaki T, Otsuki A, Terauchi M, Aoyagi R, Sato T, Fujii Y, Fujiwara T, Hanaoka H, Hata A; KAICA trial Investigators. Hamada H, et al. Among authors: okuma y. Lancet. 2019 Mar 16;393(10176):1128-1137. doi: 10.1016/S0140-6736(18)32003-8. Epub 2019 Mar 7. Lancet. 2019. PMID: 30853151 Clinical Trial.
Commentary: Progressive Encephalomyelitis with Rigidity and Myoclonus and Myasthenia Gravis Comorbid Status with Thymoma.
Balint B, Ogawa T, Ogaki K, Daida K, Nishimaki T, Ando M, Kawajiri S, Wada R, Noda K, Hattori N, Okuma Y, Barsottini O. Balint B, et al. Among authors: okuma y. Mov Disord Clin Pract. 2021 Sep 3;8(Suppl 1):S14-S15. doi: 10.1002/mdc3.13303. eCollection 2021 Aug. Mov Disord Clin Pract. 2021. PMID: 34514037 Free PMC article. No abstract available.
497 results